Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by l-DOPA?†

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Philosophical Transactions of the Royal Society B: Biological Sciences

• Publication date

  2015-07-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1098/rstb.2014.0190PMID 26009769PMCID PMC4455759
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of

  2020cited by this paper
• Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.

  2015cited by this paper
• Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.

  2015cited by this paper
• Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.

  2015cited by this paper
• Differential Effects of Synaptic and Extrasynaptic NMDA Receptors on Aβ-Induced Nitric Oxide Production in Cerebrocortical Neurons

  2014cited by this paper
• Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications

  2014cited by this paper
• Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.

  2014cited by this paper
• Striatal Cholinergic Cell Ablation Attenuates l-DOPA Induced Dyskinesia in Parkinsonian Mice

  2014cited by this paper
• Local control of striatal dopamine release

  2014cited by this paper
• Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.

  2013cited by this paper
• IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates

  2013cited by this paper
• Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications.

  2013cited by this paper
• Counteraction by Nitric Oxide Synthase Inhibitor of Neurochemical Alterations of Dopaminergic System in 6-OHDA-Lesioned Rats Under l-DOPA Treatment

  2013cited by this paper
• Extrasynaptic Neurotransmission in the Modulation of Brain Function. Focus on the Striatal Neuronal–Glial Networks

  2012cited by this paper
• 7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson's disease.

  2012cited by this paper
• Investigations into Potential Extrasynaptic Communication between the Dopaminergic and Nitrergic Systems

  2012cited by this paper
• Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.

  2012cited by this paper
• Fiji: an open-source platform for biological-image analysis

  2012cited by this paper
• Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.

  2012cited by this paper
• Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.

  2011cited by this paper
• Synaptic and Extrasynaptic NMDA Receptors Differentially Modulate Neuronal Cyclooxygenase-2 Function, Lipid Peroxidation, and Neuroprotection

  2011cited by this paper
• BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.

  2011cited by this paper
• Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.

  2011cited by this paper
• The role of nitric oxide in prostaglandin biology; update.

  2011cited by this paper
• Nitric Oxide Synthase Inhibitor Improves De Novo and Long-Term l-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats

  2011cited by this paper
• Molecular mechanisms of l-DOPA-induced dyskinesia.

  2011cited by this paper
• Dopamine release in the basal ganglia.

  2011influential reference
• Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation

  2011cited by this paper
• Calbindin‐1 association and Parkinson’s disease

  2010cited by this paper
• Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERK-dependent COX-2/PGE(2) activation.

  2010cited by this paper
• Non‐synaptic receptors and transporters involved in brain functions and targets of drug treatment

  2010cited by this paper
• Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

  2010cited by this paper
• Striatal Overexpression of ΔFosB Reproduces Chronic Levodopa-Induced Involuntary Movements

  2010cited by this paper
• Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.

  2010cited by this paper
• Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

  2010cited by this paper
• Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats.

  2010cited by this paper
• Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

  2010cited by this paper
• Enhanced striatal cholinergic neuronal activity mediates l-DOPA–induced dyskinesia in parkinsonian mice

  2010cited by this paper
• Inflammation and Parkinson's disease pathogenesis

  2010cited by this paper
• Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.

  2009cited by this paper
• The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.

  2009cited by this paper
• Calcium homeostasis, selective vulnerability and Parkinson's disease.

  2009cited by this paper
• Neuroinflammation in Parkinson's disease: a target for neuroprotection?

  2009cited by this paper
• Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.

  2009cited by this paper
• CXCR4 and CXCL12 Expression is Increased in the Nigro-Striatal System of Parkinson’s Disease

  2009cited by this paper
• Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway.

  2008cited by this paper
• Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology.

  2008cited by this paper
• Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.

  2008cited by this paper
• S-nitrosylation/activation of COX-2 mediates NMDA neurotoxicity

  2008cited by this paper
• Molecular mechanisms of L-DOPA-induced dyskinesia

  2008cited by this paper
• Author ' s personal copy EXOGENOUS CORTICOSTERONE REDUCES L-DOPA-INDUCED DYSKINESIA IN THE HEMI-PARKINSONIAN RAT : ROLE FOR INTERLEUKIN-1

  2008cited by this paper
• Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice.

  2008cited by this paper
• Prostaglandin E2 Acts on EP1 Receptor and Amplifies Both Dopamine D1 and D2 Receptor Signaling in the Striatum

  2007cited by this paper
• Neuroinflammation in the pathophysiology of Parkinson's disease: Evidence from animal models to human in vivo studies with [11C]‐PK11195 PET

  2007cited by this paper
• p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.

  2007cited by this paper
• The role of nitric oxide in inflammatory reactions.

  2007cited by this paper
• p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain

  2007cited by this paper
• Differential gene expression patterns in cyclooxygenase-1 and cyclooxygenase-2 deficient mouse brain

  2007cited by this paper
• Pretreatment with PTD-Calbindin D 28k Alleviates Rat Brain Injury Induced by Ischemia and Reperfusion

  2007cited by this paper
• Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in l-DOPA-Induced Dyskinesia

  2007cited by this paper
• Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.

  2006cited by this paper
• Estradiol modulation of kainic acid-induced calcium elevation in neonatal hippocampal neurons.

  2006cited by this paper
• Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity

  2006cited by this paper
• In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.

  2006cited by this paper
• Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats

  2006cited by this paper
• Synaptic and vascular associations of neurons containing cyclooxygenase-2 and nitric oxide synthase in rat somatosensory cortex.

  2005cited by this paper
• Microglial activation and dopamine terminal loss in early Parkinson's disease

  2005cited by this paper
• Modulation of Prostaglandin Biosynthesis by Nitric Oxide and Nitric Oxide Donors

  2005cited by this paper
• Modeling Cooperative Volume Signaling in a Plexus of Nitric Oxide Synthase-Expressing Neurons

  2005cited by this paper
• Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines

  2005cited by this paper
• The Janus Face of Cyclooxygenase-2 in Ischemic Stroke: Shifting Toward Downstream Targets

  2005cited by this paper
• Simultaneous glutamate and GABA(A) receptor agonist administration increases calbindin levels and prevents hippocampal damage induced by either agent alone in a model of perinatal brain injury.

  2005cited by this paper
• Dopamine and noradrenaline control distinct functions in rodent microglial cells.

  2005cited by this paper
• Optimising levodopa therapy for the management of Parkinson’s disease

  2005cited by this paper
• Optimising levodopa therapy for the management of Parkinson’s disease

  2005cited by this paper
• Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease

  2004cited by this paper
• Neuroprotective Function of the PGE2 EP2 Receptor in Cerebral Ischemia

  2004cited by this paper
• How does Parkinson's disease begin? The role of compensatory mechanisms.

  2004cited by this paper
• Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.

  2004cited by this paper
• Chronic l‐DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease

  2004cited by this paper
• Cyclooxygenase‐2 (COX‐2) in Inflammatory and Degenerative Brain Diseases

  2004cited by this paper
• Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

  2004cited by this paper
• DARPP-32: an integrator of neurotransmission.

  2004cited by this paper
• Developmental and cell type‐specific expression of the neuronal marker NeuN in the murine cerebellum

  2003cited by this paper
• COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice

  2003cited by this paper
• Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

  2003cited by this paper
• The Role of Glial Reaction and Inflammation in Parkinson's Disease

  2003cited by this paper
• D1 Dopamine Receptor Supersensitivity in the Dopamine-Depleted Striatum Animal Model of Parkinson’s Disease

  2003cited by this paper
• Nitric oxide and superoxide in inflammation and immune regulation.

  2003cited by this paper
• Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia

  2003cited by this paper
• Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity.

  2002cited by this paper
• Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra.

  2002cited by this paper
• L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

  2002cited by this paper
• Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease

  2002cited by this paper
• Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment.

  2002cited by this paper
• Nitric oxide in immunity and inflammation.

  2001cited by this paper
• Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease

  2001cited by this paper
• Prostaglandin biology.

  2001cited by this paper
• Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.

  2000cited by this paper
• Cyclooxygenase-2 Contributes to Functional Hyperemia in Whisker-Barrel Cortex

  2000cited by this paper

• Spinosin enhances non-rapid eye movement sleep and alters c-Fos expression in sleep–wake regulatory brain regions in mice

  2025cites this paper
• Involvement of Neuroinflammation and Oxidative Stress in L-DOPA-Induced Dyskinesia in Parkinson’s Disease: Role of Renin–Angiotensin System and ROCK Pathway

  2025cites this paper
• Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.

  2025cites this paper
• Persistent COX-2 upregulation in L-DOPA-induced dyskinesia is unaffected by inhibition with celecoxib.

  2025cites this paper
• Sex-related differences in cannabidiol's antinociceptive efficacy in a trigeminal neuralgia rodent model.

  2025cites this paper
• Neuroinflammation and Dyskinesia: A Possible Causative Relationship?

  2024cites this paper
• Unveiling differential gene co-expression networks and its effects on levodopa-induced dyskinesia

  2024cites this paper
• NOS2 and COX-2 Co-Expression Promotes Cancer Progression: A Potential Target for Developing Agents to Prevent or Treat Highly Aggressive Breast Cancer

  2024cites this paper
• 4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.

  2024cites this paper
• Dynamic Involvement of Striatal NG2-glia in L-DOPA Induced Dyskinesia in Parkinsonian Rats: Effects of Doxycycline

  2023influential citation
• ONO-2506 can delay levodopa-induced dyskinesia in the early stage.

  2023cites this paper
• Effects of hydrogen gas inhalation on L-DOPA-induced dyskinesia.

  2023cites this paper
• can delay

  2023cites this paper
• DOXYCYCLINE TO TREAT LEVODOPA-INDUCED DYSKINESIAS IN PARKINSON'S DISEASE: A PROOF-OF-CONCEPT STUDY

  2022cites this paper
• Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study

  2022cites this paper
• Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model

  2022cites this paper
• Effects of mangiferin and its combination with nNOS inhibitor 7‐nitro‐indazole (7‐NI) in 6‐hydroxydopamine (6‐OHDA) lesioned Parkinson's disease rats

  2022cites this paper
• Intercellular Communication in the Central Nervous System as Deduced by Chemical Neuroanatomy and Quantitative Analysis of Images: Impact on Neuropharmacology

  2022cites this paper
• Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys

  2022cites this paper
• Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson’s Disease: Focus on Neuroinflammation

  2021cites this paper
• Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson’s Disease

  2021cites this paper
• Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway

  2021cites this paper
• Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson’s Disease and L-DOPA-Induced Dyskinesia

  2021cites this paper
• Doxycycline and its derivative, COL‐3, decrease dyskinesia induced by l‐DOPA in hemiparkinsonian rats

  2021cites this paper
• The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.

  2021cites this paper
• Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats

  2021cites this paper
• Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats.

  2021cites this paper
• New Insights into Pathogenesis of L-DOPA-Induced Dyskinesia.

  2021cites this paper
• Doxycycline Therapeutic Approach in Parkinson’s Disease and L-DOPA-Induced Dyskinesia

  2021cites this paper
• Metabolic profile in plasma and CSF of levodopa-induced dyskinesia of Parkinson's disease

  2020cites this paper
• Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease

  2020cites this paper
• Neuroprotective Properties of Green Tea (Camellia sinensis) in Parkinson’s Disease: A Review

  2020cites this paper
• The Role of Brain Cyclooxygenase-2 (Cox-2) Beyond Neuroinflammation: Neuronal Homeostasis in Memory and Anxiety

  2020cites this paper
• ATP Signaling Controlling Dyskinesia Through P2X7 Receptors

  2020cites this paper
• The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications.

  2020cites this paper
• Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on l-Dopa induced dyskinesia

  2019cites this paper
• Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia

  2019cites this paper
• Immunomodulatory drugs alleviate l‐dopa‐induced dyskinesia in a rat model of Parkinson's disease

  2019cites this paper
• Dynamics and Modulation of Synaptic Transmission in the Mammalian CNS

  2019cites this paper
• Repurposing an established drug: an emerging role for methylene blue in L‐DOPA‐induced dyskinesia

  2018influential citation
• Extrasynaptic Neurotransmission Mediated by Exocytosis and Diffusive Release of Transmitter Substances

  2018cites this paper
• Differential behavioral and glial responses induced by dopaminergic mechanisms in the iNOS knockout mice

  2018cites this paper
• Neuroinflammation in l-DOPA-induced dyskinesia: beyond the immune function

  2018cites this paper
• Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease

  2017cites this paper
• Investigating chondroitin sulphate proteoglycans as a therapeutic target for Parkinson's disease

  2017cites this paper
• l‐DOPA‐induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?

  2017cites this paper
• l‐DOPA‐induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

  2016cites this paper
• Nanomedicine to Overcome Current Parkinson’s Treatment Liabilities: A Systematic Review

  2016cites this paper
• Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson’s Disease

  2016cites this paper
• Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?

  2016cites this paper
• Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.

  2016cites this paper
• Release of chemical transmitters from cell bodies and dendrites of nerve cells

  2015cites this paper